Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixa...
Saved in:
| Published in | PloS one Vol. 14; no. 8; p. e0221500 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
26.08.2019
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0221500 |
Cover
| Abstract | To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care.
From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up.
We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83).
After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. |
|---|---|
| AbstractList | To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care.OBJECTIVETo compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care.From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up.METHODSFrom nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up.We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83).RESULTSWe included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83).After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban.CONCLUSIONAfter 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up. We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83). After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. Methods From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up. Results We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71–1.28) for dabigatran, 1.12 (95% CI 0.87–1.45) for rivaroxaban and 0.97 (95% CI 0.75–1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62–0.86) for dabigatran, 0.97 (95% CI 0.84–1.12) for rivaroxaban and 0.71 (95% CI 0.62–0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14–0.56), rivaroxaban (HR 0.40, 95% CI 0.23–0.69) and apixaban (HR 0.56, 95% CI 0.34–0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52–0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55–0.81) and apixaban (HR 0.70, 95% CI 0.59–0.83). Conclusion After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up. We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83). After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. ObjectiveTo compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care.MethodsFrom nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up.ResultsWe included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83).ConclusionAfter 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. Methods From nationwide registries, we identified treatment-naïve patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up. Results We included 30,820 treatment-naïve patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71–1.28) for dabigatran, 1.12 (95% CI 0.87–1.45) for rivaroxaban and 0.97 (95% CI 0.75–1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62–0.86) for dabigatran, 0.97 (95% CI 0.84–1.12) for rivaroxaban and 0.71 (95% CI 0.62–0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14–0.56), rivaroxaban (HR 0.40, 95% CI 0.23–0.69) and apixaban (HR 0.56, 95% CI 0.34–0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52–0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55–0.81) and apixaban (HR 0.70, 95% CI 0.59–0.83). Conclusion After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban. |
| Audience | Academic |
| Author | Ellekjær, Hanne Karlstad, Øystein Skovlund, Eva Kjerpeseth, Lars J. Ariansen, Inger Selmer, Randi |
| AuthorAffiliation | 1 Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway 3 Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway 2 Chronic Diseases and Ageing, Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway Institut d'Investigacions Biomediques de Barcelona, SPAIN 4 Stroke Unit, Department of Internal Medicine, St. Olav’s Hospital, Trondheim, Norway |
| AuthorAffiliation_xml | – name: 3 Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway – name: 4 Stroke Unit, Department of Internal Medicine, St. Olav’s Hospital, Trondheim, Norway – name: 1 Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway – name: 2 Chronic Diseases and Ageing, Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway – name: Institut d'Investigacions Biomediques de Barcelona, SPAIN |
| Author_xml | – sequence: 1 givenname: Lars J. orcidid: 0000-0002-2033-736X surname: Kjerpeseth fullname: Kjerpeseth, Lars J. – sequence: 2 givenname: Randi surname: Selmer fullname: Selmer, Randi – sequence: 3 givenname: Inger surname: Ariansen fullname: Ariansen, Inger – sequence: 4 givenname: Øystein surname: Karlstad fullname: Karlstad, Øystein – sequence: 5 givenname: Hanne surname: Ellekjær fullname: Ellekjær, Hanne – sequence: 6 givenname: Eva surname: Skovlund fullname: Skovlund, Eva |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31449560$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9uK2zAQhk3Z0j20b1BaQ6G00KSSbEv2XhRC6CGwsNDTrRjLUqKgSK5kZ3efpS9bOYeSLEspvvBo_M0_mvHMeXJinZVJ8hyjMc4Yfr90vbdgxm10jxEhuEDoUXKGq4yMKEHZyYF9mpyHsESoyEpKnySnGc7zqqDoLPk9dasWPHR6LVOplBSDZWUIqVPpDXgFXtt3aQO1nkPnIdper8G7W6jBpmCbFFq9PWibxkuO1mDWvQGfRl6DSZWuvTYm5nD2Mp2kdmPd6Eam7QL8CoSTbTyttDNurkUMCV3f3D1NHiswQT7bvS-SH58-fp9-GV1df55NJ1cjQQnpRiWjdSFlwRTLWNEghEssgQFmSLFo4bwmNBZMKypoIxRkSiBSUFoTREXBsovk5Va3NS7wXV8DJ6REOUMUZ5GYbYnGwZK3Xq_A33EHmm8czs85-E4LI3lFiGpQUzQSypw1dVWLusY5FEAqgimKWh922fp6JRshbeyqORI9_mL1gs_dmlOGqgrjKPBmJ-Ddr16Gjq90EDI22ErXb-6NMcEZHSp7dQ99uLodNYdYgLbKxbxiEOWTomI5xbQqIzV-gIrP8ONEHEKlo_8o4O1RQGQ6edvNoQ-Bz759_X_2-ucx-_qAXUgw3SI40w9DFY7BF4ed_tvi_fRH4HILCO9C8FJxobvNcMbStOEY8WHV9k3jw6rx3arF4Pxe8F7_n2F_AMoFMC8 |
| CitedBy_id | crossref_primary_10_1002_joa3_13160 crossref_primary_10_1093_aje_kwad201 crossref_primary_10_1186_s43044_021_00194_1 crossref_primary_10_1093_ehjcvp_pvz086 crossref_primary_10_23736_S0026_4806_21_07432_2 crossref_primary_10_3390_jcm9051398 crossref_primary_10_1111_jcpt_13514 crossref_primary_10_1002_pds_5296 crossref_primary_10_1002_pds_5026 crossref_primary_10_3390_jcm11133788 crossref_primary_10_1002_clc_24146 crossref_primary_10_1093_ehjqcco_qcab048 crossref_primary_10_7759_cureus_30303 crossref_primary_10_2174_18741924_v16_e2202281 crossref_primary_10_1016_j_dld_2020_04_032 crossref_primary_10_1186_s12875_022_01824_6 crossref_primary_10_4236_wjcd_2024_141004 crossref_primary_10_1055_s_0040_1713889 crossref_primary_10_1016_j_pharmthera_2020_107676 |
| Cites_doi | 10.1007/s00228-017-2296-1 10.1038/sj.clpt.6100249 10.1371/journal.pone.0135834 10.1093/europace/eus305 10.1016/S0140-6736(10)61194-4 10.1093/eurheartj/ehq278 10.1038/nrcardio.2014.118 10.1093/ehjcvp/pvw031 10.1213/ane.0b013e31819bceb1 10.1161/CIRCULATIONAHA.112.142158 10.1007/s00228-018-2540-3 10.1016/j.thromres.2016.02.023 10.1161/JAHA.115.001798 10.1016/j.amjmed.2014.05.013 10.1161/STROKEAHA.117.017549 10.1016/j.amjmed.2015.05.044 10.1111/j.1742-7843.2009.00494.x 10.1007/s00228-017-2289-0 10.1056/NEJMoa1107039 10.1056/NEJMoa0905561 10.1136/bmjopen-2017-018180 10.3390/jcm8040554 10.1161/STROKEAHA.118.021990 10.1038/clpt.2011.235 10.1136/thoraxjnl-2013-204282 10.1111/joim.12628 10.1056/NEJMoa1310907 10.1159/000107789 10.2147/POR.S156521 10.1111/bcp.13299 10.1007/s40471-015-0053-5 10.1097/EDE.0b013e3181d61eeb 10.1056/NEJMoa1009638 10.1002/brb3.900 10.2147/CLEP.S103346 10.1007/s40273-014-0152-z 10.1016/j.ijcard.2015.11.067 10.1016/j.jacc.2017.03.540 10.1001/archinte.165.10.1095 10.1177/1403494815621641 10.1007/s00228-017-2374-4 10.1093/aje/kwg231 10.1002/pds.4581 10.1161/JAHA.113.000521 10.1002/hep.21404 10.1002/pds.4216 10.1002/pds.4217 10.1001/jamainternmed.2013.1579 10.1371/journal.pone.0202575 10.1111/bcp.13150 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 Public Library of Science 2019 Kjerpeseth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 Kjerpeseth et al 2019 Kjerpeseth et al |
| Copyright_xml | – notice: COPYRIGHT 2019 Public Library of Science – notice: 2019 Kjerpeseth et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 Kjerpeseth et al 2019 Kjerpeseth et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0221500 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Science in Context ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Database ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine Public Health |
| DocumentTitleAlternate | Effectiveness and safety of DOACs vs warfarin in non-valvular atrial fibrillation |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2280470613 oai_doaj_org_article_922fd0d5dea847db9bcbb14a5a292160 PMC6709911 A597461698 31449560 10_1371_journal_pone_0221500 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GeographicLocations | Europe Norway |
| GeographicLocations_xml | – name: Europe – name: Norway |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c622t-876b5ee57f7375d00181ea7a170f71ea14b26144696c6dcfa3fc02566b206c573 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:08 EST 2021 Wed Aug 27 01:24:45 EDT 2025 Thu Aug 21 13:52:40 EDT 2025 Fri Sep 05 14:02:11 EDT 2025 Fri Jul 25 10:50:41 EDT 2025 Tue Jun 17 21:07:39 EDT 2025 Tue Jun 10 20:46:23 EDT 2025 Fri Jun 27 04:24:46 EDT 2025 Fri Jun 27 04:46:28 EDT 2025 Thu May 22 21:21:10 EDT 2025 Mon Jul 21 05:45:19 EDT 2025 Thu Apr 24 22:59:44 EDT 2025 Tue Jul 01 02:55:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c622t-876b5ee57f7375d00181ea7a170f71ea14b26144696c6dcfa3fc02566b206c573 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0002-2033-736X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0221500 |
| PMID | 31449560 |
| PQID | 2280470613 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_2280470613 doaj_primary_oai_doaj_org_article_922fd0d5dea847db9bcbb14a5a292160 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6709911 proquest_miscellaneous_2281121367 proquest_journals_2280470613 gale_infotracmisc_A597461698 gale_infotracacademiconefile_A597461698 gale_incontextgauss_ISR_A597461698 gale_incontextgauss_IOV_A597461698 gale_healthsolutions_A597461698 pubmed_primary_31449560 crossref_citationtrail_10_1371_journal_pone_0221500 crossref_primary_10_1371_journal_pone_0221500 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-08-26 |
| PublicationDateYYYYMMDD | 2019-08-26 |
| PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2019 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | AK Eek (pone.0221500.ref018) 2018; 74 K Furu (pone.0221500.ref024) 2010; 106 RP Giugliano (pone.0221500.ref040) 2013; 369 A Tveit (pone.0221500.ref052) 2008; 109 A Torres (pone.0221500.ref035) 2013; 68 F Rahman (pone.0221500.ref017) 2014; 11 CB Granger (pone.0221500.ref005) 2011; 365 K. Furu (pone.0221500.ref023) 2008; 18 H Stovring (pone.0221500.ref030) 2017; 26 LN Marzec (pone.0221500.ref014) 2017; 69 NR Desai (pone.0221500.ref013) 2014; 127 LJ Kjerpeseth (pone.0221500.ref007) 2017; 73 JL Lund (pone.0221500.ref028) 2015; 2 M Lipsitch (pone.0221500.ref034) 2010; 21 JP Piccini (pone.0221500.ref049) 2014; 3 LR Oie (pone.0221500.ref032) 2018; 8 J Komen (pone.0221500.ref036) 2017; 73 A Mitchell (pone.0221500.ref022) 2019; 8 H Stovring (pone.0221500.ref029) 2017; 26 European Association for Cardio-Thoracic S (pone.0221500.ref006) 2010; 31 S Mueller (pone.0221500.ref039) 2018; 9 N Mochalina (pone.0221500.ref016) 2016; 140 T Forslund (pone.0221500.ref038) 2017 S Halvorsen (pone.0221500.ref025) 2017; 3 AJ Camm (pone.0221500.ref001) 2012; 14 MR Patel (pone.0221500.ref004) 2011; 365 HT Sorensen (pone.0221500.ref019) 2006; 44 L Wallentin (pone.0221500.ref051) 2010; 376 T Varmdal (pone.0221500.ref054) 2016; 44 G Ntaios (pone.0221500.ref021) 2017; 48 GR Shroff (pone.0221500.ref048) 2013; 173 TC Villines (pone.0221500.ref043) 2015; 114 JM Thrane (pone.0221500.ref031) 2018; 27 LJ Kjerpeseth (pone.0221500.ref008) 2018; 74 J Komen (pone.0221500.ref015) 2017; 83 S Gulati (pone.0221500.ref042) 2018; 13 K Gadsboll (pone.0221500.ref010) 2017; 38 WA Ray (pone.0221500.ref027) 2003; 158 SJ Connolly (pone.0221500.ref003) 2009; 361 SY Loo (pone.0221500.ref012) 2017; 83 S Schneeweiss (pone.0221500.ref026) 2011; 90 A Gundlund (pone.0221500.ref037) 2017; 282 L Huiart (pone.0221500.ref011) 2018; 8 PS Nishtala (pone.0221500.ref044) 2016; 203 AM Holbrook (pone.0221500.ref002) 2005; 165 T Forslund (pone.0221500.ref047) 2018; 49 N McCormick (pone.0221500.ref033) 2015; 10 GD Barnes (pone.0221500.ref009) 2015; 128 N. Mackman (pone.0221500.ref041) 2009; 108 JC Lauffenburger (pone.0221500.ref045) 2015; 4 L Wallentin (pone.0221500.ref050) 2013; 127 T Wisloff (pone.0221500.ref046) 2014; 32 V Malmo (pone.0221500.ref053) 2016; 8 S. Schneeweiss (pone.0221500.ref020) 2007; 82 |
| References_xml | – volume: 73 start-page: 1417 issue: 11 year: 2017 ident: pone.0221500.ref007 article-title: Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-017-2296-1 – year: 2017 ident: pone.0221500.ref038 article-title: Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study publication-title: Europace – volume: 82 start-page: 143 issue: 2 year: 2007 ident: pone.0221500.ref020 article-title: Developments in post-marketing comparative effectiveness research publication-title: Clin Pharmacol Ther doi: 10.1038/sj.clpt.6100249 – volume: 114 start-page: 1290 issue: 6 year: 2015 ident: pone.0221500.ref043 article-title: A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system publication-title: Thromb Haemost – volume: 10 start-page: e0135834 issue: 8 year: 2015 ident: pone.0221500.ref033 article-title: Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review publication-title: PLoS One doi: 10.1371/journal.pone.0135834 – volume: 14 start-page: 1385 issue: 10 year: 2012 ident: pone.0221500.ref001 article-title: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association publication-title: Europace doi: 10.1093/europace/eus305 – volume: 376 start-page: 975 issue: 9745 year: 2010 ident: pone.0221500.ref051 article-title: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61194-4 – volume: 31 start-page: 2369 issue: 19 year: 2010 ident: pone.0221500.ref006 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq278 – volume: 11 start-page: 639 issue: 11 year: 2014 ident: pone.0221500.ref017 article-title: Global epidemiology of atrial fibrillation publication-title: Nat Rev Cardiol doi: 10.1038/nrcardio.2014.118 – volume: 3 start-page: 28 issue: 1 year: 2017 ident: pone.0221500.ref025 article-title: A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvw031 – volume: 108 start-page: 1447 issue: 5 year: 2009 ident: pone.0221500.ref041 article-title: The role of tissue factor and factor VIIa in hemostasis publication-title: Anesth Analg doi: 10.1213/ane.0b013e31819bceb1 – volume: 127 start-page: 2166 issue: 22 year: 2013 ident: pone.0221500.ref050 article-title: Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.142158 – volume: 74 start-page: 1653 issue: 12 year: 2018 ident: pone.0221500.ref008 article-title: Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-018-2540-3 – volume: 140 start-page: 94 year: 2016 ident: pone.0221500.ref016 article-title: Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study publication-title: Thromb Res doi: 10.1016/j.thromres.2016.02.023 – volume: 4 start-page: e001798 issue: 4 year: 2015 ident: pone.0221500.ref045 article-title: Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study publication-title: J Am Heart Assoc doi: 10.1161/JAHA.115.001798 – volume: 127 start-page: 1075 issue: 11 year: 2014 ident: pone.0221500.ref013 article-title: Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications publication-title: Am J Med doi: 10.1016/j.amjmed.2014.05.013 – volume: 48 start-page: 2494 issue: 9 year: 2017 ident: pone.0221500.ref021 article-title: Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis publication-title: Stroke doi: 10.1161/STROKEAHA.117.017549 – volume: 128 start-page: 1300 issue: 12 year: 2015 ident: pone.0221500.ref009 article-title: National Trends in Ambulatory Oral Anticoagulant Use publication-title: Am J Med doi: 10.1016/j.amjmed.2015.05.044 – volume: 106 start-page: 86 issue: 2 year: 2010 ident: pone.0221500.ref024 article-title: The Nordic countries as a cohort for pharmacoepidemiological research publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2009.00494.x – volume: 73 start-page: 1315 issue: 10 year: 2017 ident: pone.0221500.ref036 article-title: Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-017-2289-0 – volume: 365 start-page: 981 issue: 11 year: 2011 ident: pone.0221500.ref005 article-title: Apixaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1107039 – volume: 361 start-page: 1139 issue: 12 year: 2009 ident: pone.0221500.ref003 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 8 start-page: e018180 issue: 3 year: 2018 ident: pone.0221500.ref011 article-title: Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases publication-title: BMJ Open doi: 10.1136/bmjopen-2017-018180 – volume: 8 issue: 4 year: 2019 ident: pone.0221500.ref022 article-title: Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies publication-title: Journal of clinical medicine doi: 10.3390/jcm8040554 – volume: 49 start-page: 2122 issue: 9 year: 2018 ident: pone.0221500.ref047 article-title: Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants publication-title: Stroke doi: 10.1161/STROKEAHA.118.021990 – volume: 90 start-page: 777 issue: 6 year: 2011 ident: pone.0221500.ref026 article-title: Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.235 – volume: 68 start-page: 1057 issue: 11 year: 2013 ident: pone.0221500.ref035 article-title: Risk factors for community-acquired pneumonia in adults in Europe: a literature review publication-title: Thorax doi: 10.1136/thoraxjnl-2013-204282 – volume: 282 start-page: 164 issue: 2 year: 2017 ident: pone.0221500.ref037 article-title: Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant? publication-title: J Intern Med doi: 10.1111/joim.12628 – volume: 369 start-page: 2093 issue: 22 year: 2013 ident: pone.0221500.ref040 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1310907 – volume: 109 start-page: 258 issue: 4 year: 2008 ident: pone.0221500.ref052 article-title: Atrial fibrillation and antithrombotic therapy in a 75-year-old population publication-title: Cardiology doi: 10.1159/000107789 – volume: 9 start-page: 1 year: 2018 ident: pone.0221500.ref039 article-title: Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset publication-title: Pragmatic and observational research doi: 10.2147/POR.S156521 – volume: 83 start-page: 2096 issue: 9 year: 2017 ident: pone.0221500.ref012 article-title: Trends in the prescription of novel oral anticoagulants in UK primary care publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13299 – volume: 38 start-page: 899 issue: 12 year: 2017 ident: pone.0221500.ref010 article-title: Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark publication-title: Eur Heart J – volume: 2 start-page: 221 issue: 4 year: 2015 ident: pone.0221500.ref028 article-title: The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application publication-title: Curr Epidemiol Rep doi: 10.1007/s40471-015-0053-5 – volume: 21 start-page: 383 issue: 3 year: 2010 ident: pone.0221500.ref034 article-title: Negative controls: a tool for detecting confounding and bias in observational studies publication-title: Epidemiology doi: 10.1097/EDE.0b013e3181d61eeb – volume: 365 start-page: 883 issue: 10 year: 2011 ident: pone.0221500.ref004 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 8 start-page: e00900 issue: 2 year: 2018 ident: pone.0221500.ref032 article-title: Validation of intracranial hemorrhage in the Norwegian Patient Registry publication-title: Brain Behav doi: 10.1002/brb3.900 – volume: 8 start-page: 185 year: 2016 ident: pone.0221500.ref053 article-title: Validation of self-reported and hospital-diagnosed atrial fibrillation: the HUNT study publication-title: Clin Epidemiol doi: 10.2147/CLEP.S103346 – volume: 32 start-page: 601 issue: 6 year: 2014 ident: pone.0221500.ref046 article-title: Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation publication-title: Pharmacoeconomics doi: 10.1007/s40273-014-0152-z – volume: 203 start-page: 746 year: 2016 ident: pone.0221500.ref044 article-title: 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand publication-title: . Int J Cardiol doi: 10.1016/j.ijcard.2015.11.067 – volume: 69 start-page: 2475 issue: 20 year: 2017 ident: pone.0221500.ref014 article-title: Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.03.540 – volume: 165 start-page: 1095 issue: 10 year: 2005 ident: pone.0221500.ref002 article-title: Systematic overview of warfarin and its drug and food interactions publication-title: Arch Intern Med doi: 10.1001/archinte.165.10.1095 – volume: 44 start-page: 143 issue: 2 year: 2016 ident: pone.0221500.ref054 article-title: Comparison of the validity of stroke diagnoses in a medical quality register and an administrative health register publication-title: Scand J Public Health doi: 10.1177/1403494815621641 – volume: 74 start-page: 323 issue: 3 year: 2018 ident: pone.0221500.ref018 article-title: Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-017-2374-4 – volume: 18 start-page: 129 issue: 2 year: 2008 ident: pone.0221500.ref023 article-title: Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway publication-title: Nor J Epidemiol – volume: 158 start-page: 915 issue: 9 year: 2003 ident: pone.0221500.ref027 article-title: Evaluating medication effects outside of clinical trials: new-user designs publication-title: Am J Epidemiol doi: 10.1093/aje/kwg231 – volume: 27 start-page: 1011 issue: 9 year: 2018 ident: pone.0221500.ref031 article-title: Empirical validation of the reverse parametric waiting time distribution and standard methods to estimate prescription durations for warfarin publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4581 – volume: 3 start-page: e000521 issue: 2 year: 2014 ident: pone.0221500.ref049 article-title: Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial publication-title: J Am Heart Assoc doi: 10.1161/JAHA.113.000521 – volume: 44 start-page: 1075 issue: 5 year: 2006 ident: pone.0221500.ref019 article-title: Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies publication-title: Hepatology doi: 10.1002/hep.21404 – volume: 26 start-page: 900 issue: 8 year: 2017 ident: pone.0221500.ref029 article-title: Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4216 – volume: 26 start-page: 909 issue: 8 year: 2017 ident: pone.0221500.ref030 article-title: Estimating medication stopping fraction and real-time prevalence of drug use in pharmaco-epidemiologic databases. An application of the reverse waiting time distribution publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4217 – volume: 173 start-page: 159 issue: 2 year: 2013 ident: pone.0221500.ref048 article-title: Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992–2007) publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2013.1579 – volume: 13 start-page: e0202575 issue: 8 year: 2018 ident: pone.0221500.ref042 article-title: Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study publication-title: PLoS One doi: 10.1371/journal.pone.0202575 – volume: 83 start-page: 642 issue: 3 year: 2017 ident: pone.0221500.ref015 article-title: Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13150 |
| SSID | ssj0053866 |
| Score | 2.4311802 |
| Snippet | To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial... Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial... ObjectiveTo compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial... Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0221500 |
| SubjectTerms | Aged Aging Analysis Anticoagulants Apixaban Atrial fibrillation Atrial Fibrillation - drug therapy Atrial Fibrillation - epidemiology Bleeding Cardiac arrhythmia Censorship Chronic illnesses Dabigatran - adverse effects Dabigatran - therapeutic use Disease prevention Dosage and administration Drug therapy Embolism Female Fibrillation Follow-Up Studies Hazards Health hazards Health risks Health sciences Humans Identification methods Ischemia Male Medicine Medicine and Health Sciences Patients People and Places Practice guidelines (Medicine) Public health Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyridones - adverse effects Pyridones - therapeutic use Research and Analysis Methods Rivaroxaban Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Safety Statistical analysis Statistical models Stroke Studies Transient ischemic attack Treatment Outcome Warfarin Warfarin - adverse effects Warfarin - therapeutic use |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBthiEBEhNG-dhb7gtFVVBAiSgqLfI8QNWWjmrfbT8F_4sM7Y3bVClcuASJfEkSmbG80jG3xDyQuhagFeQqWJMpSVXNpUWNszWmqGGaP9p4OMnfnJafjirzq60-sKasAAPHBh3WOe51ZmutJFgSHVbt6ptWSkrmdc54z5bz-psk0wFGwyzmPO4UK4Q7DDK5WDeOXMAXguioGzgiDxef2-VR_NZt7wu5Py7cvKKKzq-S-7EGJJOwrNvkVvG3SNbcZYu6asIJf36Pvl9dAnuTUPpRrRutLP0Qi4spMpun2rZItQG-K19upiey0X3S7bSUek0lfNpOJg66jqXgmqeY-0qlb7jB7W4aGAWSure0AkNnxcvptrQecTFNpdtaFEnqMe0fUBOj999OzpJYzuGVPE8X6HdbCtjKmFFISqN7fyYkUIykVkBe6xsc59e1lxxrawsrMKIird5xlUliodkBI9ptgkFgULYAu5zPObluGTSCggFVSnxZhABJaTYyKZREascW2bMGv8DTkDOEljdoESbKNGEpP1V84DVcQP9WxR7T4tI2_4E6F8T9a-5Sf8S8hSVpgnLVnt70UwwU-OM1-OEPPcUiLbhsJznh1wvl837z9__gejrlwHRy0hkO2CHknEJBbwTongNKHcGlGAz1GB4G1V8w5Vlg6BIpcDYDq7cqP31w8_6Ybwplug50609DUN8QC4S8ijMkp6zBagFJuIJEYP5M2D9cMRNf3qwc8QXBIf8-H_I6gm5DfFujb8Ecr5DRqvF2uxCTLlq97z5-APqU3iq priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3raxQxEA_1CiKI2PPR06pRBBW67WUfya0gci0tVegp1ZZ-W7LJpi4cu-s9Wv8X_1lnstk9V4r65bjbzIZcMq8kM78h5KXQsQCrID3FmPJCrownDXwwE2uGHKLt0cDxhB-dhh_Po_M1MmlyYTCsstGJVlHrUuEZ-S7CtoQCrc_76ruHVaPwdrUpoSFdaQX9zkKM3SDroJKjYY-s7x1MPp80uhmkm3OXQBcItuvWa6cqi2wHrBl4R8OOgbI4_q227lXTcn6dK_pnROVvJurwLrnjfEs6rplhg6xlRZ_cPHa3531yuz6jo3XqUZ9sOMGe09cOffrNPfJzf4UHTutoD6cQaWnolZwZ2F0X21TLFNE5wNRt01l-KWflD5nKgspCU1nl9Y-8oEVZeMDNlxjuSqUtEkIN5hlM6yi8t3RM6xPJq1xntHJQ2tmqci2yEbUwuPfJ6eHB1_0jz1Vw8BT3_QWq2jTKskgYEYhIYwVAlkkhmRgaAd9YmPp2RxpzxbUyMjAKnTCe-kOuIhE8ID0YZrZJqB5q8HTA4o5GPByFTBoB3qMKJXYGTtOABM2yJcrBm2OVjWli7-wEbHPqVUhwsRO32APitW9VNbzHP-j3kCNaWgTntg_K2UXiZD2Jfd_AcCOdSbD9Oo1TlaYslJH0Y59x6OQZ8lNSZ7q2KiYZ4-aOMx6PBuSFpUCAjgIjgC7kcj5PPnw6-w-iLycdoleOyJQwHUq6rAv4Twj81aHc6lCCmlGd5k3k_mZW5slKIOHNRiKub37eNmOnGNVXZOXS0jCEFORiQB7WAtTObABsgXv3AREd0epMfbelyL9ZfHSEJAQb_ujvw3pMboHzG-P9gM-3SG8xW2ZPwMFcpE-d1vgF-LR-FQ priority: 102 providerName: ProQuest |
| Title | Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31449560 https://www.proquest.com/docview/2280470613 https://www.proquest.com/docview/2281121367 https://pubmed.ncbi.nlm.nih.gov/PMC6709911 https://doaj.org/article/922fd0d5dea847db9bcbb14a5a292160 http://dx.doi.org/10.1371/journal.pone.0221500 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELdGJ6G9IMa_FUYxCAmQlqpOE7tBQqirVgYSAw2K-hY5djwqVUlJ2218Fr4sd46TEVQE4iVq67OVnu98d_b5d4Q8FToSYBWkpxhTXsCV8aSBBzORZigh2m4NvD_hx5Pg3TScbpGqZqtj4HJjaIf1pCbFvHv57ftrUPhXtmqDYFWn7iLP0i7YJPBxIIjftidGmMwX1OcKoN2cuwt0f-q5Q673IcrAuKFhqyykf71wtxbzfLnJK_09ufIXazW-SW44N5MOS7nYJVtpdovsOkVe0ucObfrFbfJjdIX_TcvsDrcA0tzQC1kYiKazA6plgmgcYNoOaDE7l0V-KROZUZlpKhez8ssso1meeSC955jeSqUtCkIN3iuYl1l3L-mQljuQFzOd0oWDzk6vKtWi2FALe3uHTMZHn0fHnqvY4Cnu-ytcWpMwTUNhRF-EGiv-sVQKyUTPCPjEgsS3EWjEFdfKyL5R6HTxxO9xFYr-XdKC10z3CNU9DZ4NzOBgwINBwKQR4C2qQOJg4CS1Sb-am1g5OHOsqjGP7RmdgLCmZHWMkxu7yW0Tr-61KOE8_kJ_iNNe0yIYt_0hL85ip9tx5PsGXjfUqQRbr5MoUUnCAhlKP_IZh0EeodDE5c3WekmJhxjMccajQZs8sRQIyJFhxs-ZXC-X8dsPX_6B6NNpg-iZIzI5sENJd8sC_hMCfTUo9xuUsKyoRvMeinjFlWWMuEmBQPcPelZiv7n5cd2Mg2IWX5bma0vDEEKQiza5V2pJzdlK59pENPSnwfpmSzb7avHQEYIQbPb9_-75gOyAHxzhUYHP90lrVazTh-BrrpIOuSamAp6DEcPn-E2HbB8enXw87djdm45dXn4CH3WHqA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJwESQqy8rDCYQSBAWrY6TewGaULd2NSytUNjQ_sWHDselaqk9GWF38J_4bdxlzgtQRPwZV-qNr5Yrn2-O5_vniPkudCBAK0gHcWYcjyujCMNfDATaIYcojPXQLfH26fe-zP_bIn8LHJhMKyykImZoNapQh_5FsK2eAK1z9vhVwerRuHtalFCQ9rSCno7gxiziR0H8fcZHOHG2513sN4vXHd_72S37dgqA47irjtBcRD5cewLIxrC11iljsVSSCbqRsA35kVudmoKuOJaGdkwCg0FHrl1rnzRgH6vkWUPHSgVsryz1_twXOgCkCac24S9hmBblj82h2kSb4L2BGusXlKIWd2AuXaoDAfp-DLT988Izt9U4v4dctvasrSVM98KWYqTKrnetbf1VXIr9wnSPNWpSlasIBnTVxbt-vVd8mN3gT9O8-gSK4BpauhMjgyc5pMNqmWEaCCgWjfoqH8hR-k3GcmEykRTOeznP_oJTdLEgd1zgeG1VGZFSajBvIZBHvX3hrZo7gGd9XVMhxa6O15UykW2pRns7j1yeiVreZ9UYJjxKqG6rsGyAg3fbHKv6TFpBFirypPYGRhpNdIoli1UFk4dq3oMwuyOUMCxKl-FEBc7tItdI878rWEOJ_IP-h3kiDktgoFnD9LReWhlSxi4roHh-jqWYGvoKIhUFDFP-tINXMahk3XkpzDPrJ2LtLCFh0nOeNCskWcZBQKCJBhxdC6n43HYOfr0H0Qfj0tELy2RSWE6lLRZHvCfEGisRLlWogSxpkrNq8j9xayMw4UAgDeLHXF589N5M3aKUYRJnE4zGoYQhlzUyIN8A81ntgFsgb6CGhGlrVWa-nJL0v-S4bEjBCLYDA__Pqx1cqN90j0MDzu9g0fkJhjeAd5NuHyNVCajafwYjNtJ9MRKEEo-X7XQ-gWqTrma |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGkSYkhFh5WWEwg0CAtKx1XuwGCaGyUa2MjQkY6rfg2PGoVCWh7Vb4LfwTfh13iZsSNAFf9qVq44vl-s73Yp-fI-SR0KEAqyAdxZhyfK6MIw18MBNqhhKii62Bg0O-d-y_GQbDFfJzcRcG0yoXOrFQ1DpTuEfeRtgWX6D1aRubFnG023-Zf3WwghSetC7KaZQisp98n0P4Nn0x2AVeP3bd_uuPO3uOrTDgKO66M1QFcZAkgTDCE4HGCnUskUIy0TECvjE_douIKeSKa2WkZxQ6CTx2O1wFwoN-L5HLwvN9LBshhlWwB3qEc3tVzxOsbSVjO8_SZBvsJvhhnZopLCoGVHahkY-z6XlO75-5m78Zw_51cs16sbRXit0aWUnSJlk9sOf0TXK13A2k5SWnJlmzKmRKn1qc62c3yI-dJfI4LfNKrOqlmaFzOTEQx6dbVMsYcUDAqG7RyehMTrJvMpYplammMh-VP0YpTbPUgXVzhom1VBblSKjBGw3jMt_vOe3Rcu9zPtIJzS1od7KskYsCSwvA3Zvk-EI4eYs0YJjJOqG6o8GnAtve7XK_6zNpBPipypfYGbhnLeIt2BYpC6SO9TzGUXE6KCCgKrkQIbMjy-wWcaq38hJI5B_0r1AiKlqEAS8eZJOTyGqVKHRdA8MNdCLBy9BxGKs4Zr4MpBu6jEMnmyhPUXmntlJmUQ_DSM542G2RhwUFQoGkuKhO5Ol0Gg3effoPog_va0RPLJHJYDqUtPc74D8hxFiNcqNGCQpN1ZrXUfoXszKNlksf3lysiPObH1TN2CnmD6ZJdlrQMAQv5KJFbpcLqJpZD8QCdwlaRNSWVm3q6y3p6EuBxI7gh-At3Pn7sDbJKqiq6O3gcP8uuQIed4iHEi7fII3Z5DS5B17tLL5fqA9KPl-0vvoFpC-3Ng |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+effectiveness+of+warfarin%2C+dabigatran%2C+rivaroxaban+and+apixaban+in+non-valvular+atrial+fibrillation%3A+A+nationwide+pharmacoepidemiological+study&rft.jtitle=PloS+one&rft.au=Kjerpeseth%2C+Lars+J.&rft.au=Selmer%2C+Randi&rft.au=Ariansen%2C+Inger&rft.au=Karlstad%2C+%C3%98ystein&rft.date=2019-08-26&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=14&rft.issue=8&rft_id=info:doi/10.1371%2Fjournal.pone.0221500&rft_id=info%3Apmid%2F31449560&rft.externalDocID=PMC6709911 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |